Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia To Consider New Drug Price Caps In Next Year’s Budget

This article was originally published in PharmAsia News

Executive Summary

Australia's federal government plans to lower the caps on the price of the medicines it covers when it considers next year's budget later this year. Drug makers are being advised by the Health Ministry that the budget might go after company profits if the current practice of discounts and incentives to pharmacists to push drugs is not restrained. The discounts get passed on to the consumer, Minister Nicola Roxon said, and the government does not feel the Pharmaceutical Benefits Scheme should be propping up industry profits, particularly in the current economic climate. (Click here for more

You may also be interested in...



Coverage Decisions For AlloMap Molecular Testing To Detect Cardiac Allograft Rejections Left Up To MACs

The US CMS has proposed that due to low Medicare use, it will not nationally cover AlloMap molecular tests to detect cardiac allograft rejections.

FDA Advises Caution, Consultation Before Using 99.99% Germ-Killing Claims On Sanitizers

Manufacturers considering use of the popular 99.99% germ-kill claim on hand sanitizer products should consult the Office of Compliance, said Division of Nonprescription Drug Products director Theresa Michele during a recent industry workshop. “Be very, very cautious about the claims you are making,” she said.

Preparing To Lead EMA, Cooke Routes Road Ahead For Pharma Regulation At Agency Conference

Change in leadership at the European Medicines Agency comes at a critical time.

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel